Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vectorite BiomedicalROCO:4170 +0.81%65 Altman Z-Score is 14.70 as of Jul. 14, 2026, which is 17% below its 10-year median of 17.76. GuruFocus rates ROCO:4170 with a GF Score™ of 65/100 and a GF Value™ of NT$17.56 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 928 Biotechnology companies, Vectorite Biomedical ranks better than 82.33% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 14.6 is strong.
Vectorite Biomedical has a Altman Z-Score of 14.70, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Vectorite Biomedical's Altman Z-Score or its related term are showing as below:
ROCO:4170'
s Altman Z-Score Range Over the Past 10 Years
Min: 4.66 Med: 17.76 Max: 26.94
Current: 14.6
During the past 13 years, Vectorite Biomedical's highest Altman Z-Score was 26.94. The lowest was 4.66. And the median was 17.76.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Vectorite Biomedical Altman Z-Score Related Terms
Vectorite Biomedical Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Vectorite Biomedical's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4170 vs VRTX, REGN, ALNY: Altman Z-Score Comparison
For the Biotechnology subindustry, Vectorite Biomedical's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vectorite Biomedical Altman Z-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vectorite Biomedical's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Vectorite Biomedical's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Vectorite Biomedical's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.3448
+
1.4
*
0.0972
+
3.3
*
0.1887
+
0.6
*
22.3487
+
1.0
*
0.1205
=
14.70
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Vectorite Biomedical (ROCO:4170) has a Altman Z-Score of 14.70 as of Jul. 14, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Vectorite Biomedical and its competitors. This is 17% below median its historical median of 17.76. Over the past decade, Vectorite Biomedical's Altman Z-Score has ranged from 4.66 to 26.94. According to the industry distribution chart, Vectorite Biomedical ranks #164 out of 928 companies in the Biotechnology industry, placing it in the top 17.7%.
Is Vectorite Biomedical's Altman Z-Score too high?
Vectorite Biomedical's current Altman Z-Score of 14.70 is 17% below median its 10-year median of 17.76. Over the past 10 years, this metric has ranged from a low of 4.66 to a high of 26.94. The Biotechnology industry median Altman Z-Score is 2.69. Vectorite Biomedical's value of 14.70 is 446.5% above this industry median. Based on the distribution chart, Vectorite Biomedical ranks #164 out of 928 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Vectorite Biomedical has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vectorite Biomedical's Altman Z-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vectorite Biomedical ranks #164 out of 928 companies for Altman Z-Score. This places Vectorite Biomedical in the top 18% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 2.69. Vectorite Biomedical's value of 14.70 is 446.5% above this benchmark. Historically, Vectorite Biomedical's own Altman Z-Score has ranged from 4.66 to 26.94 over the past decade. While the company's 10-year median is 17.76 vs. the industry median of 2.69, Vectorite Biomedical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Biotechnology company?
The median Altman Z-Score among Biotechnology companies is 2.69, based on 928 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vectorite Biomedical's current Altman Z-Score of 14.70 is 446.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Vectorite Biomedical and its competitors. For the Biotechnology industry, the median Altman Z-Score is 2.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vectorite Biomedical's current Altman Z-Score is 14.70, which is 17% below median its own 10-year median of 17.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vectorite Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Vectorite Biomedical (ROCO:4170) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$17.56, compared to a current price of NT$12.50 — trading 28.8% below its estimated fair value. The current Altman Z-Score is 14.70, which is 17% below median its 10-year median of 17.76 and 446.5% above the Biotechnology industry median of 2.69. Vectorite Biomedical's overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Vectorite Biomedical (ROCO:4170), the current Altman Z-Score is 14.70 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vectorite Biomedical (ROCO:4170) Overvalued in 2026?
Based on GuruFocus' analysis, Vectorite Biomedical stock appears to be undervalued.
The current stock price of NT$12.50 is trading 28.8% below its estimated GF Value™ of NT$17.56.
GuruFocus considers Vectorite Biomedical to be Modestly Undervalued.
Key valuation signals for ROCO:4170:
Altman Z-Score: 14.70 (17% below median its 10-year median of 17.76)
GF Value™: NT$17.56 vs. price of NT$12.50 (28.8% below fair value)
Industry Position: 446.5% above the Biotechnology median (#164 of 928)
No single metric tells the full story. See the ROCO:4170 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vectorite Biomedical Inc is a Taiwan-based biotechnology research and development, cell product (preparation) manufacturing and immune cell collection and storage business.
65GF Score
Get the complete analysis for ROCO:4170
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4170 has been successfully added to your 
